ALXNUnknown
ALEXION PHARMACEUTICALS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for ALEXION PHARMACEUTICALS, INC. (ALXN), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ALXN insiders buying or selling?
ALEXION PHARMACEUTICALS, INC. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 30 Form 4 filings for ALXN: 3 buys ($40.7M) and 27 sells ($49.8M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Dec 21, 2020)
Total Form 4 filings
30
SEC EDGAR
Insider filers
14
Insider buys (3)
$40.7M
Insider sells (27)
$49.8M
Insider sentiment
Net sellingNet insider flow of $9.1M in net selling since January 2018.
Recent ALXN insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 21, 2020 | Daniel Bazarko | SVP, Controller, CAO | Sale | 24.1K | $157.70 | $3.8M | SEC ↗ |
| Dec 4, 2020 | Tanisha Carino | EVP & CCAO | Sale | 1.5K | $122.26 | $187.1K | SEC ↗ |
| Jun 9, 2020 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sale | 6.9K | $114.69 | $786.0K | SEC ↗ |
| Mar 18, 2020 | Felix Baker | Director | Purchase | 81.4K | $82.01 | $6.7M | SEC ↗ |
| Mar 18, 2020 | Felix Baker | Director | Purchase | 418.6K | $78.33 | $32.8M | SEC ↗ |
| Jul 2, 2019 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sale | 4.5K | $132.78 | $597.5K | SEC ↗ |
| Jun 24, 2019 | Aradhana Sarin | Chief Strategy & Business Off | Sale | 578 | $132.00 | $76.3K | SEC ↗ |
| May 30, 2019 | Felix Baker | Director | Sale | 300.0K | $123.74 | $37.1M | SEC ↗ |
| Feb 20, 2019 | Daniel Bazarko | SVP, Controller, CAO | Sale | 2.0K | $126.00 | $252.0K | SEC ↗ |
| Jan 3, 2019 | Ludwig Hantson | CEO | Sale | 3.2K | $95.85 | $310.9K | SEC ↗ |
| Nov 30, 2018 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sale | 2.6K | $118.13 | $307.7K | SEC ↗ |
| Jul 12, 2018 | Paul J Clancy | EVP, Chief Financial Officer | Sale | 5.2K | $131.11 | $687.1K | SEC ↗ |
| Jun 12, 2018 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sale | 1.5K | $118.53 | $173.8K | SEC ↗ |
| Jun 12, 2018 | Anne-Marie Law | EVP and CHRO | Sale | 1.9K | $118.53 | $220.7K | SEC ↗ |
| Jun 12, 2018 | Brian Goff | EVP & Chief Commercial Officer | Sale | 1.6K | $118.53 | $195.0K | SEC ↗ |
| Jun 12, 2018 | John J Orloff | EVP, Research & Development | Sale | 2.1K | $118.53 | $250.7K | SEC ↗ |
| May 2, 2018 | COUGHLIN CHRISTOPHER J | Director | Purchase | 10.0K | $120.79 | $1.2M | SEC ↗ |
| Mar 1, 2018 | Julie O'Neill | EVP. Global Operations | Sale | 1.6K | $119.83 | $194.7K | SEC ↗ |
| Mar 1, 2018 | Heidi L Wagner | SVP, Global Government Affairs | Sale | 698 | $119.35 | $83.3K | SEC ↗ |
| Feb 9, 2018 | Brian Goff | EVP & Chief Commercial Officer | Sale | 1.7K | $116.31 | $192.0K | SEC ↗ |
| Feb 9, 2018 | Heidi L Wagner | SVP, Global Government Affairs | Sale | 1.8K | $116.31 | $206.3K | SEC ↗ |
| Feb 9, 2018 | Paul J Clancy | EVP, Chief Financial Officer | Sale | 6.1K | $116.31 | $707.0K | SEC ↗ |
| Feb 9, 2018 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sale | 1.5K | $116.31 | $169.7K | SEC ↗ |
| Feb 9, 2018 | Julie O'Neill | EVP. Global Operations | Sale | 4.8K | $116.31 | $556.8K | SEC ↗ |
| Feb 9, 2018 | John B Moriarty | EVP & General Counsel | Sale | 3.4K | $115.70 | $389.1K | SEC ↗ |
Showing the 25 most recent of 30 Form 4 filings for ALEXION PHARMACEUTICALS, INC..
Most active ALXN insiders
- Indrani Lall Franchini5 filings
- Felix Baker3 filings
- Heidi L Wagner3 filings
- Julie O'Neill3 filings
- Ludwig Hantson3 filings
Ask anything about ALXN insider activity
Use Trabud's AI agent to query ALEXION PHARMACEUTICALS, INC.'s Form 4 history in plain English — "Show me ALXN CEO purchases this year" or compare it against any other ticker.
Open the AI agentALXN insider trading FAQ
Are ALEXION PHARMACEUTICALS, INC. insiders buying or selling?
ALEXION PHARMACEUTICALS, INC. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 30 Form 4 filings for ALXN: 3 buys ($40.7M) and 27 sells ($49.8M). Over the full record that is net selling of $9.1M.
How many insiders trade ALXN stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for ALEXION PHARMACEUTICALS, INC.. The most recent filing was accepted on Dec 21, 2020.
Where does Trabud get ALXN insider trading data?
All ALXN insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.